- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04040933
A Study to Assess Wound Healing Efficacies of Different Adhesive Bandages
June 28, 2023 updated by: Johnson & Johnson Consumer Inc. (J&JCI)
A 28-Day, Single-Center, Randomized, Comparator-Controlled, Proof-of-Principle Study to Assess Wound Healing Efficacies of Different Adhesive Bandages
The purpose of this study is to assess the wound healing efficacy (time to complete healing) of different adhesive bandages.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Richardson, Texas, United States, 75081
- Thomas J. Stephens
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Fitzpatrick Skin Type II or III
- Uniform skin color on both volar forearms
- Generally in good health based on medical history reported by the participant
- -Individual has signed the Photographic Release and Informed Consent Documents along with (HIPAA) disclosure
- Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms
Exclusion Criteria:
- Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, latex, wound treatment products, or any component/ingredient present in the Investigational Products (IPs)/auxiliary/ancillary products
- Has a known history of a blood-clotting disorder, keloid formation, or a cardiovascular, hepatic, or renal disease
- Presents with a skin condition that would, in the opinion of the PI or Study Physician, confound study results, increase risk to participant, or interfere with study evaluations
- Has excessive hair or tattoos on either volar forearm
- Has a known history of severe systemic immune system disorders
- Has self-reported Type 1 or Type 2 diabetes
- Has self-reported uncontrolled chronic diseases
- Is taking medication that would mask an adverse event, confound study results or alter/compromise the bleeding/healing process
- Is self-reported to be pregnant or planning to become pregnant
- Has a body mass index (BMI) above 35
- Is self-reported to be an alcohol or drug abuser
- Has participated in another clinical trial within 10 days
- Either is or lives with someone who is a current employee of any company that makes/markets adhesive bandages or first-aid products
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Marketed Adhesive Bandage #1
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a marketed adhesive bandage will be applied.
|
Active Comparator: Marketed Adhesive Bandage #2
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a marketed adhesive bandage will be applied.
|
Active Comparator: Non-marketed Adhesive Bandage #1
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a non-marketed adhesive bandage will be applied.
|
Experimental: Non-marketed Adhesive Bandage #2
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a non-marketed adhesive bandage will be applied.
|
Experimental: Non-marketed Adhesive Bandage #3
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a non-marketed adhesive bandage will be applied.
|
Experimental: Non-marketed Adhesive Bandage #4
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a non-marketed adhesive bandage will be applied.
|
Experimental: Non-marketed Adhesive Bandage #5
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, bandage will be applied.
This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
|
On the randomized wound site, a non-marketed adhesive bandage will be applied.
|
No Intervention: No Treatment (Uncovered, Negative Control)
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist.
On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Complete Wound Healing
Time Frame: Up to Day 16
|
Time to complete wound healing: time(in days) elapsed from time of wound creation to 12 PM of day (up to Day 16) on which composite healing score(CHS) first meets complete healing criterion of being at least a score of 8 (threshold for complete healing).
CHS was calculated from clinical grading of wound healing parameters as general wound appearance (0 [Poor-New or fresh wound with epithelium layer missing, wound bed appears raw and possibly oozing] to 4 [Excellent-Fully healed, skin flush against surrounding skin, slight color mismatch may be present])+smoothness (0 [Rough, uneven wound]- 4 [complete smoothness, even wound])+epithelial confluence (0 [None]- 4 [91-100%full epithelial growth]) - erythema (0 [None]- 4 [Severe]) - edema (0 [None]- 4 [Severe]) - crusting/scabbing (0 [None]- 4 [90-100% crusting/scabbing]).
CHS on 25-point scale (-12 [no healing] to +12 [towards healing]) is indicative of extent of wound healing and was calculated for each wound site at each evaluation day.
|
Up to Day 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Trans-Epidermal Water Loss (TEWL) Measurements
Time Frame: Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
|
Change from Baseline in TEWL was reported.
TEWL is the passive transfer of water through stratum corneum and was measured for each wound site using Tewameter TM330T.
TEWL is a non-invasive method to measure the integrity of stratum corneum barrier function.
Tewameter probe measures the density gradient of the water evaporation from the skin indirectly by two pairs of sensors (temperature and relative humidity) inside a hollow cylinder.
The probe was held in place on the skin for one measurement, for 40 sec, to ensure that a stable value has been established.
The values of the last 10 sec are averaged as the actual measurement values.
An increase in TEWL values shows damage to the skin barrier function.
|
Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
|
Change From Baseline in Clinical Grading of Wound Healing Parameter - Erythema
Time Frame: Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
|
Change from baseline in Clinical grading of wound healing parameter (erythema) was evaluated on a scale of 0 (no erythema) to 4 (severe erythema).
|
Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
|
Change From Baseline in Clinical Grading of Wound Healing Parameter - Edema
Time Frame: Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
|
Change from baseline in Clinical grading of wound healing parameter (edema) was evaluated on a scale of 0 (no edema) to 4 (severe edema).
|
Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
|
Change From Baseline in Composite Scar Score
Time Frame: Baseline and Day 28
|
Change from baseline in composite scar score was reported.
It was calculated as the sum of the individual parameters on the Manchester Scar Scale (Color ranges 1 [perfect] to 4 [gross mismatch]), Finish ranges 1 [matte] to 2 [shiny], Contour ranges 1 [Flush with surrounding skin] to 4 [keloid], Distortion ranges 1 [none] to 4 [severe] and Texture ranges 1 [normal] to 4 [hard]).
Composite Scar Scores range from 5 to 18, with 5 representing clinically best scars and 18 representing clinically worst scars.
|
Baseline and Day 28
|
Change From Baseline in Painful Score With Arm Resting by Side
Time Frame: Baseline, Day 1, 2, 3 and 4
|
Change from baseline in painful score based on participants self-assessment questionnaire score (question 1) was reported.
Participants were asked to rate each wound for pain/soreness in resting position as score from 0 (no pain) to 10 (severe pain).
|
Baseline, Day 1, 2, 3 and 4
|
Change From Baseline in Painful Score With Arm in Normal Motion
Time Frame: Baseline, Day 1, 2, 3 and 4
|
Change from baseline in Painful Score based on participants self-assessment questionnaire score (question 3) was reported.
Participants were asked to rate each wound for pain/soreness in normal position as score from 0 (no pain) to 10 (severe pain).
|
Baseline, Day 1, 2, 3 and 4
|
Change From Baseline in Itchy Score
Time Frame: Baseline, Day 1, 2, 3 and 4
|
Change from baseline in itchy score based on participants self-assessment questionnaire score (question 5) was reported.
Participants were asked to rate each wound for itchiness as score from 0 (no itch) to 10 (severe itch).
|
Baseline, Day 1, 2, 3 and 4
|
Number of Participants With Pain Duration With Arm Resting by Side
Time Frame: Day 1, 2, 3 and 4
|
Participants were asked to rate the pain as either brief, periodic, or constant in arm resting position with the Self-Assessment Questionnaire (question 2).
Number of participants with pain duration (brief, periodic, or constant) with arm resting by side was reported.
|
Day 1, 2, 3 and 4
|
Number of Participants With Pain Duration With Arm in Normal Motion
Time Frame: Day 1, 2, 3 and 4
|
Participants were asked to rate the pain as either brief, periodic, or constant in arm normal motion with the Self-Assessment Questionnaire (question 4).
Number of participants with pain duration (brief, periodic, or constant) with arm in normal motion was reported.
|
Day 1, 2, 3 and 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lily Jiang, PhD, Thomas J. Stephens & Associates, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 9, 2019
Primary Completion (Actual)
October 18, 2019
Study Completion (Actual)
October 30, 2019
Study Registration Dates
First Submitted
July 30, 2019
First Submitted That Met QC Criteria
July 30, 2019
First Posted (Actual)
August 1, 2019
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 28, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCSTOH001689 (Other Identifier: Johnson & Johnson Consumer Inc. (J&JCI))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Johnson & Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health.
Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound Healing
-
University of Witten/HerdeckeKCI Europe Holding B.V.CompletedImpaired Wound Healing | Wound Healing Disorder | Abdominal Wound Healing Disorder | Abdominal Wound Healing Impairment | Acute Postsurgical Subcutaneous WoundBelgium, Germany
-
Universidade Estadual Paulista Júlio de Mesquita...RecruitingWound Healing | Palate; WoundBrazil
-
Stratpharma AGUniversity Hospital, GenevaCompleted
-
University Hospital, GhentCompleted
-
Dow University of Health SciencesUnknown
-
Peking University Third HospitalCompleted
-
University of ChicagoCompleted
-
Bispebjerg HospitalThe Danish Medical Research CouncilCompletedWound HealingDenmark
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
Clinical Trials on Marketed Adhesive Bandage #1
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
GlaxoSmithKlineCompletedDenture RetentionUnited States
-
GlaxoSmithKlineCompletedDenture RetentionUnited States
-
Rodrigo Antonio Carvalho AndrausNot yet recruiting
-
University of AlcalaCompleted
-
Chattem, Inc.CompletedTolerability | Adhesiveness | Dermal Irritation | Effects of HeatUnited States
-
Vomaris InnovationsCompleted
-
Coloplast A/SUnknown
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited Kingdom
-
Coloplast A/SCompleted